Narrativa on Applied Clinical Trials

Los Angeles based AI company Narrativa is partnering with the Leukemia and Lymphoma Society to improve regulatory documentation. In order to achieve, the tech company is applying artificial intelligence models and automated data analysis to enhance the Beat AML Master Clinical Trial.

The trial is the first precision medicine clinical trial for blood cancer. As is the case with most precision medicine models, the trial uses advanced genomic technology to determine the best targeted treatment for each patient. The trial launched in 2016.

In a press release sent to ACT, Narrativa’s technology will automate the production of patient narratives and clinical study reports, along with other elements of the regulatory process. This should speed up the process and reduce the time it takes for new treatments to get approved and released to market.